Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
-
* Corresponding author: Roberto Ravasio Roberto.Ravasio@wolterskluwer.com
- † Equal contributors
Italian Journal of Pediatrics 2009, 35:4 doi:10.1186/1824-7288-35-4
Accesses
- Last 30 days: 43 accesses
- Last year: 496 accesses
- All time: 1872 accesses
Cited by
BioMed Central: 1 citation
|
Research
Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing Elio Coletta, Salvatore Coppolino, Febronia Federico, Francesco Fulia Italian Journal of Pediatrics 2010, 36:48 (7 July 2010) |
